COVID-19: Excellent antibody cocktail effect! : Chugai Ronapreve
-Ronapreve sales of 82.3 billion yen-
Chugai’s financial results announcement:
The momentum of Chugai Pharmaceutical Co., Ltd., a major pharmaceutical company, has not stopped.
On October 22, the financial results for the January-September period of 2021 were announced.
Sales increased 17% year-on-year to 677.4 billion yen
Operating profit increased 24% year-on-year to 282.8 billion yen.
What should be noted in this settlement of accounts is
Antibody cocktail therapy for new type of roller treatment
The remedy “Rona Preve”.
Therapeutic drug “Ronapreve”:
In the July-September period, sales of this one drug alone were 82.3 billion yen.
Supply contract with the Japanese government:
Chugai obtained approval for Rona Preve in July this year.
He had a supply contract with the Japanese government for 2021.
Sales in the first year of release:
Until now, the amount of supply and the price per person have not been disclosed.
That became clear in this financial statement.
By bulk purchase by the government
Sales in the first year of release
A new drug that costs more than 80 billion yen is unusual.
Antibody cocktail therapy:
Ronapreve is a blend of two different types of antibodies that suppress the growth of the virus in the body.
That is the origin of the name “cocktail”.
As a result, it is easy to keep the effect even if the virus is mutated.
Produced by American Regeneron
Chugai and its parent company Roche of Switzerland
We have been conducting clinical trials.
Ronapreve clinical trial results:
In the group of mildly ill patients who received Ronapreve, the rate of hospitalization and death was reduced by 70%.
In addition, in the placebo group
It took 14 days to recover from the symptoms,
The Ronapreve group shrank to 10 days.
Former Prime Minister Yoshihide Suga:
On October 12, he appeared and explained on a live YouTube program.
The Japanese government
Rona Preve for 310,000 yen each time
He revealed that he had procured 500,000 times.
Pharmaceuticals / Bio | Toyo Keizai Online
https://toyokeizai.net/articles/-/466097?display=b
Oct 11,2021
Chugai Files for Additional Indications of Antibody Cocktail Ronapreve for Prophylaxis of COVID-19 and Treatment of Asymptomatic COVID-19
The application is submitted for additional indication for prophylaxis of COVID-19 and treatment of asymptomatic COVID-19.
The application contains additional subcutaneous administration.
The application is based on the results from
a global phase III study in people who live in the same household with an individual infected with COVID-19,
a global phase II study to examine the dosage and dosing regimen,
and a phase I study in the Japanese population.
The application seeks Special Approval for Emergency.
News | CHUGAI PHARMACEUTICAL CO., LTD.
https://www.chugai-pharm.co.jp/english/news/detail/20211011170001_856.html